Scenarios that move JNJ
Johnson & Johnson Common Stock
Scenarios that move JNJ: 15 analyses, 8 positive, 7 negative.
- · Opus Genetics receives FDA approval for presbyopia eye drop — ▼ · impact -25 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▼ · impact -22 · confidence medium · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +73 · confidence medium · horizon immediate
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +30 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +40 · confidence low · horizon quarters
- · Pacira BioSciences shares skyrocket in today's trading — ▼ · impact -25 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -8 · confidence low · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +17 · confidence medium · horizon weeks
- · United Therapeutics stock rises 12.6% in trading — ▼ · impact -10 · confidence low · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -36 · confidence medium · horizon quarters
- · Xenon files epilepsy NDA as depression study setback weighs — ▲ · impact +15 · confidence medium · horizon weeks
- · ◇ What if… US enters recession by end of 2026 — ▲ · impact +60 · confidence low · horizon quarters
- · Definium reports second Phase III success in anxiety program — ▼ · impact -25 · confidence low · horizon quarters
- · Tech stocks slide as dire AI warnings send Micron down 5% — ▲ · impact +25 · confidence low · horizon weeks
- · Cooper Companies faces scrutiny as US channel inventories decline — ▲ · impact +50 · confidence low · horizon weeks